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pendix are available online.ThErythropoietin (EPO), the kidney hormone regulating erythrocyte production, activatesthe erythropoietin receptor (EPOR), resulting in antiapoptosis. To investigate theclinical significance of EPOR expressed in neuronal cells of the brain, EPO was
administered to patients within 8 hours of the onset of stroke symptoms, which ultimately
resulted in the reduction of cerebral infarct size and improvement of functional neurologic
performance.1
Rodents treated with EPO in an animal model of myocardial ischemia and infarction
recently demonstrated superior myocardial function.2,3 The expression of the EPOR was
shown for a variety of rodent and rabbit primary and permanent cardiomyocyte cell lines. But,
as noted by several investigators,2,3 proof of the presence of the EPOR in the adult human
heart is missing.
To overcome this deficit, we investigated adult human ventricular and atrial tissue for the
expression of the EPOR.
Methods
The study was approved by the institutional review board, and written informed consent was
obtained from all participants. In patients with severe aortic valvular stenosis (valve area  0.7
cm2), ventricular tissue was obtained from the muscular septum obstructing the left ventricular
outflow tract (Morrow procedure) and snap-frozen for RNA and protein analysis or formalin-fixed
for immunohistologic analysis (n  4 per group). Right atrial tissue from the site of the venous
cannulation was processed accordingly. Samples were analyzed with reverse transcriptase-poly-
merase chain reaction, Western blot, and standard or double immunohistochemistry as described
in the online supplement.
Results and Discussion
In this report we provide evidence of the expression of the EPOR in adult human ventricular and
atrial tissue. Western blots (Figure 1) and reverse transcriptase-polymerase chain reaction
(Figure E1) from human ventricular and atrial tissue homogenates indicate the presence of the
EPO receptor in the human heart.
Next we elucidated which cells of the human heart express the EPOR. By using standard
(anti-EPOR antibody) and double immunohistochemistry (cardiomyocyte-specific -actinin an-
tibody in combination with anti-EPOR antibody), we showed that ventricular myocytes (Figures
2 and E2, A-C) are markedly positive for EPOR. These results not only confirm the findings from
animal experiments2,3 but also expand them to the adult human situation. A novel finding of this
investigation was the presence of EPOR in human atrial myocytes (Figure E2, D, E), which had
not been described to date. In addition, we confirmed that endothelial cells in the adult human
heart are positive for EPOR (Figures 2 and E2, D). In contrast with a recent study on primary
rabbit cardiac fibroblasts,4 EPOR expression in connective tissue of the adult human ventricle
(Figure E2, C) or atria (Figure E2, D, E) was not observed. This discrepancy might reflect the
differences between cell culture and in vivo conditions or species-specific differences. The
observed subcellular distribution of the EPOR signal suggests that the EPOR is localized to
the cell membrane (Figure E2, B, insert 1) and cytoplasm (Figure E2, B, insert 2). Although
e Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 3 877.e1
Brief Communicationsthe methods used do not provide final topologic proof of the
cytoplasmic localization of the EPOR, it was recently reported that
the EPOR indeed is degraded by internalization and subsequent
targeting for lysosomal disposal. Recently, several investigations
using animal experiments of myocardial ischemia or infarction
reported significant improvements of myocardial function on treat-
ment with EPO. Because a proof of concept study in humans has
yet to be performed,3 our findings of the EPOR expression in the
human heart are particularly significant. In this context of EPO-
induced cytoprotection, it is remarkable that Leist and coworkers5
were able to dissect the hematopoietic activity from the cytopro-
tective activity. Thus, it might be possible to exploit the cytopro-
tective effect of EPO without the potentially dangerous side effect
of polycythemia.
Our findings provide primary data evidence of the presence and
localization of the EPOR in the adult human heart. They encourage
investigation of the potential of EPO administration for myocardial
Figure 1. Proof of EPOR expression in human heart. Western blot
probed with antihuman EPOR antiserum (sc-695) gave a clear
band at the expected molecular size. Lysate from the K-562 cell
line served as positive control. EPOR, Erythropoietin receptor;
-tubul, -tubulin.protection in humans.
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Methods
RNA extraction and semiquantitative reverse transcriptase-
polymerase chain reaction. Reverse transcription of RNA and
amplification of cDNA were performed in a thermal cycler
(Whatman Biometra, Florham Park, NJ). For cDNA synthesis,
reverse transcription was performed with oligo-dT priming and
Omniscript (Qiagen, Hilden, Germany) according to the man-
ufacturer’s protocol. Polymerase chain reaction was performed
in a thermal cycler (MWG-Biotech, Ebersberg, Germany) under
the following conditions: 10 mmol/L Tris-HCl (pH 9.0), 50
mmol/L KCl, 1.5 mmol/L MgCl2, 200 mol/L of each dNTP,
0.2 mol/L upstream and downstream primers, 2% reverse
transcriptase mix, and 0.1 U/L SuperTaq (Ambion Inc, Austin,
Tex). Amplification conditions were 1 minute at 94°C, 1 minute
at 56°C (erythropoietin receptor [EPOR]) at 64°C (-actin), 2
minutes at 72°C for 30 cycles, and a final extension step of 10
minutes at 72°C. Primer pairs were as follows:
5=-EPOR 5=-GGCAGTGTGGACATAGTGGC-3=
3=-EPOR 5=-AGCAGGATGGATTGGGCAGA-3=
5=--actin 5=-TGACGGGGTCACCCACACTGTGCCCAT
CTA-3=
3=--actin 5=-CTAGAAGCATTTGCGGTGGACGATGGA
GGG-3=
Western blot. Tissue was homogenized in lysis-buffer
(60 mmol/L Tris-HCl; pH 6.8, 10% glycerol, 1% Triton X-100,
Protease Inhibitor Cocktail [Calbiochem, Darmstadt, Germany]),
and protein extracts were separated on a 10% sodium dodecyl
sulfate–polyacrylamide gel and transferred to nitrocellulose mem-
branes (Hybond, Amersham Biosciences, Buckinghamshire, UK).
Protein transfer was controlled by Ponceau S staining according to
the manufacturer’s protocol (Sigma-Aldrich, St Louis, Mo). Im-
munodetection was performed with rabbit polyclonal anti-EPOR
antibody C-20 (1:100, sc695 Santa Cruz Biotechnology, Santa
Cruz, Calif). A lysate of K-562 cell (sc2203, Santa Cruz Biotech-
nology) served as positive control, and the specificity of the
antiserum was confirmed by co-incubation with blocking peptide
(sc-695p, Santa Cruz Biotechnology, data not shown). Anti--
tubulin (1:1000, Santa Cruz Biotechnology) and anti--actin anti-
body (A5691, Sigma-Aldrich) were used as loading controls. In-
cubation with primary antibody was followed by incubation with a
1:3000 dilution of goat anti-rabbit or goat anti-mouse horseradish
peroxidase-labeled antibody (BioRad, Hercules, Calif) and
visualization with enhanced chemiluminescence (Amersham
Biosciences).
Histology. Ventricular and atrial-auricular tissue were imme-
diately fixed in 4% buffered formalin (pH 7.4), processed rou-
The Journal of Thoracic atinely, and embedded in paraffin using an automatic tissue proces-
sor (Leica TP 1020, Leica, Heidelberg, Germany). Embedded
tissues were serially sectioned on a Micron microtome (HM 440E,
Micron, Neuss, Germany). The sections were examined with a
Zeiss photomicroscope (Carl Zeiss Surgical, Inc, Thornwood,
NY).
Immunohistochemistry. Immunohistochemistry was per-
formed on 2-m–thin sections. Epitopes were retrieved by heat-
induced antigen retrieval. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide. Sections were blocked
(CSA-Kit K1500, DakoCytomation, Carpinteria, Calif) and incu-
bated with anti-EPOR antiserum (sc695, recognizes C-terminus,
Santa Cruz Biotechnology, or 07-311, recognizes N-terminus,
Upstate, Lake Placid, NY) or cardiac muscle-specific anti--
actinin (A7811, Sigma, St Louis, Mo) for 15 minutes at room
temperature. Coincubation of antiserum and blocking peptide (1:1,
sc695:sc695P, Santa Cruz Biotechnology) and isotype-specific
immunoglobulin-G antibody, respectively, served as negative con-
trols (results not shown). The primary antibody was linked to an
amplification system (CSA or Envision, DakoCytomation). Chro-
mogen development with AEC, FastRed, and DAB (DakoCyto-
mation), respectively, was followed by counterstaining with
Mayer’s hemalaun (Merck, Darmstadt, Germany).
Figure E1. EPOR mRNA expression in human heart. Agarose gel
of reverse transcriptase-polymerase chain reaction showing the
presence of EPOR mRNA in ventricular and atrial tissue. Atri,
Atrium; EPO, erythropoietin.nd Cardiovascular Surgery ● Volume 130, Number 3 877.e3
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Ventricular myocytes (arrows in A and B) and endoth
Double staining (C) for ventricular myocyte-specific s
showed that the EPOR was present in myocytes, but
sarcolemma (insert 1 in B) and more evenly distributed
and endothelial cells (arrowheads, insert 4 in D) expres
recognized the C-terminal portion (sc-695) in (A) and (D
E). n, Nucleus; fibro, fibrocytes. Scale bar 10 m.he human heart by (double) immunohistochemistry. A, B, C,
elial cells (arrowheads in A) were positive for the EPOR.
arcomeric -actinin (dark brown) and EPOR (red) clearly
not in fibrocytes. The EPOR was found clustered to the
in myocytes (insert 2 in B). D, E, Atrial myocytes (arrows)
sed the EPOR. F, Negative control. The anti-EPOR antiserum
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